Calling all Takayasu’s patients!

Calling all Takayasu’s patients!

Enrollment Urgently Needed For Study in Takayasu’s Arteritis.

The Vasculitis Foundation is working with the VCRC investigators to raise awareness of a Takayasu’s arteritis (TAK) study which is enrolling patients. We are in critical need of TAK patients to participate in the study.

The challenge of this study is that not every TAK patient will qualify and/or be interested in participating. The good news is that although you have to go to one of the VCRC centers, there is travel funding available.And we have 10 centers: Boston, Cleveland, Los Angeles, New York, Philadelphia, Pittsburgh, Rochester (MN), Salt Lake City, Toronto, and Hamilton, Ontario.

Study background:
In 2007 the National Institutes of Health (NIH) funded a study to examine the medication abatacept in people with active Takayasu’s arteritis (TAK) which is being conducted by the Vasculitis Clinical Research Consortium (VCRC). This ground breaking study represents the only comparative treatment trial ever to be conducted in TAK. With this being the first such study in TAK, completing enrollment is essential in order to demonstrate that TAK studies can be readily performed. This trial is in its final months and further enrollment is critically needed to allow the study to answer its research questions.

People who have active TAK and are eligible for this study will be treated with abatacept given by vein once a month together with daily prednisone, which will be started at a dose of 40 to 60mg and then reduced. All participants will be given abatacept for the first 3 months. If there is no sign of active TAK at Month 3, participants will be randomly assigned to either continue abatacept or be switched to placebo (sterile salt water). Participants who remain in remission will continue to receive abatacept or placebo once a month until the study ends.

To be part of this study you will need to come to a VCRC center once a month. Travel funding is available. There are centers in Boston, Cleveland, Los Angeles, New York, Philadelphia, Pittsburgh, Rochester (MN), Salt Lake City, Toronto, and Hamilton, Ontario. Funding to cover travel costs to one of these Centers can be provided.

For questions regarding this study please contact Carol McAlear.